Abstract |
The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation and overall survival in white patients with non-small-cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor, gefitinib. Of 175 consecutive patients treated with oral gefitinib (250 mg/day), 170 (median age: 67 years; 72% men) were evaluable for genotyping and survival. Fifty-five patients (33%) had stable disease and 17 (10%) had an objective response. The most common of four haplotypes was G-C (EGFR*1) at the EGFR -216G>T and -191C>A loci (frequency, 0.45). After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015). The results may help identify patients with NSCLC who can benefit from gefitinib treatment.
|
Authors | V Gregorc, M Hidalgo, A Spreafico, G Cusatis, V Ludovini, R G Ingersoll, S Marsh, S M Steinberg, M G Viganò, D Ghio, E Villa, A Sparreboom, S D Baker |
Journal | Clinical pharmacology and therapeutics
(Clin Pharmacol Ther)
Vol. 83
Issue 3
Pg. 477-84
(Mar 2008)
ISSN: 1532-6535 [Electronic] United States |
PMID | 17713473
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Quinazolines
- ErbB Receptors
- Gefitinib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Brain Neoplasms
(drug therapy, mortality, secondary)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics, mortality)
- ErbB Receptors
(antagonists & inhibitors, genetics)
- Female
- Gefitinib
- Germ-Line Mutation
(genetics)
- Humans
- Lung Neoplasms
(drug therapy, genetics, mortality)
- Male
- Middle Aged
- Polymorphism, Genetic
(genetics)
- Quinazolines
(therapeutic use)
- Survival Rate
(trends)
|